Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio - Asset Resilience Ratio
Hadasit Bio (HDST) has an Asset Resilience Ratio of 57.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2022)
This chart shows how Hadasit Bio's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hadasit Bio's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA8.36 Million | 57.0% |
| Total Liquid Assets | ILA8.36 Million | 57.00% |
Asset Resilience Insights
- Very High Liquidity: Hadasit Bio maintains exceptional liquid asset reserves at 57.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hadasit Bio Industry Peers by Asset Resilience Ratio
Compare Hadasit Bio's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
Annual Asset Resilience Ratio for Hadasit Bio (2008–2022)
The table below shows the annual Asset Resilience Ratio data for Hadasit Bio.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 38.65% | ILA15.06 Million | ILA38.95 Million | +6.56pp |
| 2021-12-31 | 32.09% | ILA21.32 Million | ILA66.41 Million | -47.03pp |
| 2020-12-31 | 79.12% | ILA32.74 Million | ILA41.38 Million | +65.75pp |
| 2019-12-31 | 13.37% | ILA1.26 Million | ILA9.41 Million | +8.70pp |
| 2018-12-31 | 4.67% | ILA1.65 Million | ILA35.34 Million | -47.15pp |
| 2017-12-31 | 51.82% | ILA35.55 Million | ILA68.60 Million | +0.51pp |
| 2016-12-31 | 51.31% | ILA35.64 Million | ILA69.46 Million | +49.02pp |
| 2015-12-31 | 2.28% | ILA1.57 Million | ILA68.61 Million | -14.22pp |
| 2014-12-31 | 16.50% | ILA5.35 Million | ILA32.42 Million | -7.42pp |
| 2013-12-31 | 23.92% | ILA8.31 Million | ILA34.76 Million | -3.34pp |
| 2012-12-31 | 27.25% | ILA11.77 Million | ILA43.19 Million | -8.32pp |
| 2011-12-31 | 35.57% | ILA15.51 Million | ILA43.60 Million | -0.77pp |
| 2010-12-31 | 36.34% | ILA22.18 Million | ILA61.05 Million | -3.31pp |
| 2009-12-31 | 39.65% | ILA22.20 Million | ILA55.99 Million | +38.43pp |
| 2008-12-31 | 1.22% | ILA258.00K | ILA21.11 Million | -- |